Preferences help
enabled [disable] Abstract
Number of results
2015 | 86 | 11 | 518-522
Article title

The Role of Apolipoprotein (A) In Pathogenesis and Clinical Course of Deep Venous Thrombosis

Title variants
Languages of publication
Deep venous thrombosis is widespread disease, which complications, like: pulmonary embolism and postphlebitis syndrome areimportant social problem. There are many well-known and accurately described risk factors, though in many cases etiology remains unexplained. Further research into causes of deep venous thrombosis seem to be fully justified.The aim of the study was the evaluation of the influence of apolipoprotein (a) serum level in patients with deep venous thrombosis and the changes of its concentration during the treatment.Materials and methods. 26 patients with newly diagnosed deep venous thrombosis (DVT) were enrolled to the study. Diagnosis of DVT was established by use of physical examination and duplex Doppler. Measurements of apolipoprotein (a) and D-dimers serum level were recorded on the following days, starting from the day of the initial diagnosis: 1, 7, 14 and 84.Results. Statistically significant increase of the level of serum apolipoprotein (a) has been found during properly conducted treatment.Conclusions. Alterations of the concentration of serum apoliprotein (a) during the deep venous thrombosis treatment, indicates the involvement of apolipoprotein (a) in pathogenesis of deep venous thrombosis.
Physical description
20 - 8 - 2014
3 - 2 - 2015
  • Department of Vascular Surgery and Angiology, Medical University in Lublin Kierownik: dr hab. prof. nadzw.
  • Department of Vascular Surgery and Angiology, Medical University in Lublin Kierownik: dr hab. prof. nadzw.
  • Department of Vascular Surgery and Angiology, Medical University in Lublin Kierownik: dr hab. prof. nadzw.
  • Department of Vascular Surgery and Angiology, Medical University in Lublin Kierownik: dr hab. prof. nadzw.
  • 1. Creager MA, Dzau VJ, Loscalzo J: Choroby naczyń. Wydawnictwo Czelej Sp. z o.o. Lublin 2008; 859-84.
  • 2. Hach W: Chirurgia żył, Galaktyka Sp. z o. o. Łódź 2010.
  • 3. Noszczyk W: Chirurgia tętnic i żył obwodowych. Wydawnictwo Lekarskie PZWL, wydanie II. Warszawa 2007; 372-400.
  • 4. Zubilewicz T, Terlecki P: Żylna choroba zakrzepo-wo-zatorowa. Medi Page Sp. z o.o. Warszawa 2013.
  • 5. Hus I, Sokołowska В, Walter-Croneck A et al.: Assessment of plasma prothrombotic factors in patients with Buerger's disease. Blood Coagul Fibrinolysis. 2013; 24(2):133-9. doi: 10.1097/ MBC.0b013e32835b7272[WoS][Crossref]
  • 6. Leischik R, Dworrak B: Lipoprotein (a): importance for the fibrinolytic system and thromboembolic complications. Herz 2006; 31(2): 144-52.[PubMed][Crossref]
  • 7. Cheung MC, Albers JJ, Kennedy H et al.: Association of Apo (a) isoform size with dyslipoproteine-mia in male venous thrombosis patients. clin chim Acta 2010; 6: 411(17-18): 1279-83.[WoS]
  • 8. Ahn JH, Lee HJ, Lee Ek et al.: Antiangiogenic-kringles derived from human plasminogen and apolipoprotein (a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site. Biol chem 2011; 392(4): 347-56.[WoS]
  • 9. Barre DE: The molecular nature and consequences of lipoprotein (a)'s association with platelets. Protein Pept let 2007; 14(9): 839-42.
  • 10. Berger CE, Kröner A, stiegler H et al.: Hypofi-brinolysis, lipoprotein (a), and plasminogen activator inhibitor. clin orthop Relat res 2002; (397): 342-49.
  • 11. Discepolo W, Wun T, Berglund L: Lipoprotein (a) and thrombocytes: potential mechanisms underlying cardiovascular risk. Pathophysiol Haemost Thromb 2006; 35(3-4): 314-21.
  • 12. Feric NT, Boffa MB, Johnston SM, Koschinsky ML: Apolipoprotein (a) inhibits the conversion of Glu-plasminogen to Lys-plasminogen: a novel mechanism for lipoprotein (a)-mediated inhibition of plasminogen activation. J Thromb Haemost 2008; 6(12): 2113-20.[WoS][Crossref][PubMed]
  • 13. Hancock MA, Boffa MB, Marcovina SM et al.: Inhibition of plasminogen activation by lipoprotein (a): critical domains in apolipoprotein (a) and mechanism of inhibition on fibrin and degraded fibrin surfaces. J Biol chem 2003; 278(26): 23260-69.
  • 14. Knapp JP, Herrmann W: In vitro inhibition of fibrinolysis by apolipoprotein (a) and lipoprotein (a) is size- and concentration-dependent. clin chem Lab Med 2004; 42(9): 1013-19.[PubMed]
  • 15. Romagnuolo R, Marcovina SM, Boffa MB, Ko-schinsky ML: Inhibition of plasminogen activation by apolipoprotein (a): Role of carboxyl-terminal lysines and identification of inhibitory domains in apolipoprotein (a). J Lipid Res 2014; Jan 29. (Epub ahead of print).[Crossref][WoS]
  • 16. Vucković В, Derić M: Lipoprotein (a): a link between thrombogenesis and atherogenesis. Med Przegl 2007; 60(1-2): 37-41.[Crossref]
  • 17. Goldenberg NA, Bernard TJ, Hillhouse J et al.: Elevated lipoprotein (a), small apolipoprotein (a), and the risk of arterial ischemic stroke in North American children. Haematologica 2013; 98(5): 802-07.[Crossref][WoS]
  • 18. Hancock MA, Spencer CA, Koschinsky ML: Definition of the structural elements in plasminogen required for high-affinity binding to apolipoprotein (a): a study utilizing surface plasmon resonance. Biochemistry 2004; 28; 43(38): 12237-48.
  • 19. Hoover-Plow J, Huang M: Lipoprotein (a) metabolism: potential sites for therapeutic targets. Metabolism 2013; 62(4): 479-91.[WoS][Crossref]
  • 20. Jelaković В, Laganović M, Kuzmanić D: Lipoprotein (a) - a mysterious factor in atherogenesis. Lijec Vjesn 2002; 124(11-12): 366-71.
  • 21. de la Peña-Díaz A, Cardoso-Saldaña G, Zamora-González J et al.: Functional approach to investigate Lp (a) in ischaemic heart and cerebral diseases. Eur J clin Invest 2003; 33(2): 99-105.[Crossref]
  • 22. Spence JD: The role of lipoprotein (a) in the formation of arterial plaques, stenoses and occlusions. can J cardiol 2010; Mar; 26 Suppl A: 37A-40A.[PubMed]
  • 23. Undas A, Cieśla-Dul M, Drążkiewicz T, Sadowski J: Altered fibrin clot properties are associated with residual vein obstruction: effects of lipoprotein (a) and apolipoprotein (a) isoform. Thromb Res 2012; 130(3): 184-87.[WoS]
  • 24. Kelly J, Rudda A, Lewis RR, Hunt BJ: Plasma D-dimers in the diagnosis of venous thromboembo-lism. Arch Intern Med 2002; 162: 619-24.
  • 25. Koutroubakis IE, Malliaraki N, Vardas E et al.: Increased levels of lipoprotein (a) in Crohn's disease: A relation to thrombosis? Eur J Gastroenterol Hepatol 2001; 13(12): 1415-19.[Crossref]
  • 26. van der Graaf F, van den Borne H, van der Kolk Metai: Exclusion of deep venous thrombosis with D-Dimer testing. Comparison of 13 D-Dimer methods in 99 outpatients suspected of deep venous thrombosis using venography as reference standard. Thromb Haemost 2000; 83: 191-98.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.